Trial Information - Phase III
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)
Protocol ID: M16-191
Sponsor: AbbVie
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
